Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.
JSR will be providing the equity capital for OPM Asia that will enable the establishment of a world-class biomedical manufacturing and market development operation.
JSR will develop technologies related to maintaining homeostasis of gut microbiota and in vitro diagnostic products through the JSR-Keio University Medical and Chemical Innovation Center (JKiC).
Receive JSR Life Sciences news on your RSS reader.